Suppr超能文献

成人幽门螺杆菌感染的治疗策略。I. 2000年建议的检测与根除治疗的更新指征。

Strategy for treatment of Helicobacter pylori infection in adults. I. Updated indications for test and eradication therapy suggested in 2000.

作者信息

Nakajima S, Graham D Y, Hattori T, Bamba T

机构信息

Department of Medicine/Gastroenterology, Social Insurance Shiga Hospital, 16-1 Fujimidai, Otsu, Shiga 520-0846, Japan.

出版信息

Curr Pharm Des. 2000 Oct;6(15):1503-14. doi: 10.2174/1381612003399112.

Abstract

Since the report of culture of Helicobacter pylori in 1983, there has been increasing agreement that H. pylori infection is etiologically associated with a number of important diseases including chronic active gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lymphoma, gastric polyps, gastric cancer, as well as suggestions that it may be involved in diseases outside the upper gastrointestinal tract. There have been a number of national and international consensus meetings to propose guidelines to treat H. pylori infection. The recommendations of these conferences are reviewed here and updated to include new indications and concepts regarding H. pylori eradication therapy. Eradication therapy is considered the standard of care for active or inactive peptic ulcer patients including those who use non-steroidal anti-inflammatory drugs (NSAIDs). Other strong indications include MALT lymphoma, hyperplastic polyps, hyperplastic gastropathy, post-endoscopic resection for gastric malignancy, and acute H. pylori gastritis. Other considerations include plan to use chronic NSAID therapy, plan for chronic anti-secretory therapy, and some extra-gastroduodenal diseases such as chronic ureterica. Non-investigated dyspepsia is an indication for diagnostic evaluation and eradication therapy for those with H. pylori infection, whereas non-ulcer dyspepsia (NUD) in which peptic ulcer disease has been excluded is not an indication for evaluation per se. Intervention studies are now in progress to test the hypothesis that prevention of gastric malignancy is an outcome of H. pylori eradication. Because the prevalence of H. pylori infection and the associated diseases such as peptic ulcer or gastric cancer differ among countries as well as different approvals for treatment are required by governments or insurance agencies, the acceptable indications of eradication therapy will, by necessity, vary among countries.

摘要

自1983年幽门螺杆菌培养报告发表以来,人们越来越一致地认为,幽门螺杆菌感染在病因上与多种重要疾病相关,包括慢性活动性胃炎、消化性溃疡病、黏膜相关淋巴组织(MALT)淋巴瘤、胃息肉、胃癌,还有观点认为它可能与上消化道以外的疾病有关。已经召开了多次国内和国际共识会议,以提出治疗幽门螺杆菌感染的指南。本文对这些会议的建议进行了回顾,并进行了更新,纳入了有关幽门螺杆菌根除治疗的新适应证和概念。根除治疗被认为是活动性或非活动性消化性溃疡患者(包括使用非甾体抗炎药(NSAIDs)的患者)的标准治疗方法。其他明确的适应证包括MALT淋巴瘤、增生性息肉、增生性胃病、胃恶性肿瘤内镜切除术后以及急性幽门螺杆菌胃炎。其他需要考虑的因素包括计划使用慢性NSAIDs治疗、计划进行慢性抗分泌治疗以及一些胃十二指肠外疾病,如慢性输尿管炎。对于幽门螺杆菌感染的未调查消化不良患者,是进行诊断评估和根除治疗的适应证,而排除了消化性溃疡病的非溃疡性消化不良(NUD)本身并不是评估的适应证。目前正在进行干预研究,以检验根除幽门螺杆菌可预防胃恶性肿瘤这一假说。由于幽门螺杆菌感染的患病率以及消化性溃疡或胃癌等相关疾病在不同国家存在差异,并且政府或保险机构对治疗的批准要求也不同,因此根除治疗的可接受适应证必然会因国家而异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验